Core Viewpoint - Insilico Medicine has announced a research collaboration with a global independent pharmaceutical company, Sivea, worth a total of $888 million, focusing on the development of new cancer therapies using Insilico's AI platform, Pharma.AI [1] Group 1: Collaboration Details - The collaboration agreement includes a potential upfront payment of up to $32 million and milestone payments related to recent research developments [1] - The partnership aims to identify and develop new therapeutic drugs targeting challenging oncology areas [1] Group 2: Technology Utilization - Insilico Medicine will leverage its proprietary AI technology platform, Pharma.AI, to screen and advance potential drug candidates that meet established drug development and scientific standards [1]
英矽智能：与施维雅达成8.88亿美元抗肿瘤药物研发合作